Tendyne Holdings, Inc. is a clinical stage medical device company focused on the development of minimally invasive therapies for the treatment of mitral regurgitation. Mitral regurgitation is a condition that afflicts hundreds of thousands of individuals worldwide every year. Formed in 2010, their first product concept is a transcatheter mitral valve replacement prosthesis for the treatment of mitral regurgitation. The intent is for the valve to be deployed and secured with no disruption to the native mitral annulus while preserving the sub-valvular apparatus. Placement of the valve is intended to be completed transapically in a simple procedure where the implanting physician is able to re-position, remove, and re-deploy their valve throughout the procedure.